ABL1 and amyotrophic lateral sclerosis: Furthermore, the treatment with neurotinib, a novel allosteric c-Abl inhibitor with high brain penetrance in ALS transgenic mice mutant for superoxide 1 (SOD1), results in a delayed disease onset.